There is an increasing need for models that bridge the gap between in vitro studies and mammalian studies in order to improve the predictivity of preclinical testing and reduce late-stage attrition. Galleria mellonella larvae have been widely used over the past five years as non-mammalian models of microbial infection and for antimicrobial drug screening. More recently, the larvae have been used to test chemical toxicity and may be able to provide a more predictive screen prior to mammalian toxicity testing.
Biosystems Technology Ltd. has developed TruLarv; research grade Galleria mellonella larvae for use in chemical and drug development pipelines as early screens for assessing efficacy and toxicity. TruLarv are weight and age defined, surface decontaminated and bred without the use of antibiotics or other drugs and as a result they behave more consistently and reproducibly than larvae available from other sources.
With the support of funding from CRACK IT Solutions, the Exeter-based Biosystems Technology team is working with Envigo to compare acute oral toxicity testing of 25 compounds in G. mellonella with existing data from cell culture methods. The aim is to assess whether TruLarv provides a more accurate predictor of the mammalian LD50 than cell culture IC50 measurements.
If data obtained with TruLarv is more predictive of mammalian toxicity than existing cell culture methods, TruLarv toxicity testing will be offered as a service from Envigo, enabling wider uptake of the model by industry and reducing animal use by facilitating selection of only the most promising leads.
Full details about this CRACK IT Solution can be found on the CRACK IT website.